Topics

$1B-plus deal to advance cell therapy candidate for chronic back pain

06:33 EDT 13 Sep 2019 | SmartBrief

Mesoblast, an Australian cell therapy developer, will collaborate with the Grunenthal Group of Germany to advance development -More

Original Article: $1B-plus deal to advance cell therapy candidate for chronic back pain

NEXT ARTICLE

More From BioPortfolio on "$1B-plus deal to advance cell therapy candidate for chronic back pain"

Quick Search

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...